Literature DB >> 10219750

Mechanisms of immune regulation in the peripheral nervous system.

R Gold1, J J Archelos, H P Hartung.   

Abstract

The peripheral nervous system (PNS) is a target for heterogenous immune attacks mediated by different components of the systemic immune compartment. T cells, B cells, and macrophages can interact with endogenous, partially immune-competent glial cells and contribute to local inflammation. Cellular and humoral immune functions of Schwann cells have been well characterized in vitro. In addition, the interaction of the humoral and cellular immune system with the cellular and extracellular components in the PNS may determine the extent of tissue inflammation and repair processes such as remyelination and neuronal outgrowth. The animal model experimental autoimmune neuritis (EAN) allows direct monitoring of these immune responses in vivo. In EAN contributions to regulate autoimmunity in the PNS are made by adhesion molecules and by cytokines that orchestrate cellular interactions. The PNS has a significant potential to eliminate T cell inflammation via apoptosis, which is almost lacking in other tissues such as muscle and skin. In vitro experiments suggest different scenarios how specific cellular and humoral elements in the PNS may sensitize autoreactive T cells for apoptosis in vivo. Interestingly several conventional and novel immunotherapeutic approaches like glucocorticosteroids and high-dose antigen therapy induce T cell apoptosis in situ in EAN. A better understanding of immune regulation and its failure in the PNS may help to develop improved, more specific immunotherapies.

Entities:  

Mesh:

Year:  1999        PMID: 10219750     DOI: 10.1111/j.1750-3639.1999.tb00231.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  18 in total

1.  Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope.

Authors:  M Stienekemeier; K Falk; O Rötzschke; A Weishaupt; C Schneider; K V Toyka; R Gold; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance.

Authors:  C D Schmid; M Stienekemeier; S Oehen; F Bootz; J Zielasek; R Gold; K V Toyka; M Schachner; R Martini
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

3.  Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy.

Authors:  Hye-Jung Kim; Cha-Gyun Jung; Mark A Jensen; Danuta Dukala; Betty Soliven
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 4.  The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  Hong-liang Zhang; Jiang Wu; Jie Zhu
Journal:  J Biomed Biotechnol       Date:  2010-02-16

5.  Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 6.  Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies.

Authors:  Jolien Wolbert; Mandy I Cheng; Gerd Meyer zu Horste; Maureen A Su
Journal:  JCI Insight       Date:  2020-02-13

7.  α(M)β(2)-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro.

Authors:  Nejla Yosef; Eroboghene E Ubogu
Journal:  J Cell Physiol       Date:  2012-12       Impact factor: 6.384

8.  CD4 T cells mediate axonal damage and spinal cord motor neuron apoptosis in murine p0106-125-induced experimental autoimmune neuritis.

Authors:  Anna Brunn; Olaf Utermöhlen; Mariana Carstov; Monica Sánchez Ruiz; Hrvoje Miletic; Dirk Schlüter; Martina Deckert
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 9.  [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies].

Authors:  M Stangel; H-P Hartung; R Gold; B C Kieseier
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

10.  Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.

Authors:  E A Marsh; C L Hirst; J G Llewelyn; M D Cossburn; M M Reilly; A Krishnan; M Doran; A M Ryan; A J Coles; J L Jones; N P Robertson
Journal:  J Neurol       Date:  2010-01-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.